

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 8,076,488

Page 1 of 4

APPLICATION NO. : 10/788,426

ISSUE DATE : December 13, 2011

INVENTOR(S) : Jacques DUMAS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Cover Page, (54) Title reads: "BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS" should read -- NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS --.

Column 132, Line 9 reads: "A=1-oxo-2,3-dihydro-1H-inden-5-yl; and B=phenyl," should read -- A=1-oxo-2,3-dihydro-1H-inden-5-yl; and B=phenyl --.

Column 133, Line 29 reads: "4-[3-fluoro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[3-fluoro-4-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 32 reads: "4-[2-fluoro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[2-fluoro-4-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 35 reads: "4-[2,4-difluoro-5-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[2,4-difluoro-5-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 38 reads: "N-methyl-4-[4-((1methyl-1H-indazol-5-yl)amino]" should read -- N-methyl-4-[4-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 41 reads: "4-[4-fluoro-3-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[4-fluoro-3-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 44 reads: "4-[2-fluoro-5-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[2-fluoro-5-((1methyl-1H-indazol-5-yl)amino] --.

Column 133, Line 47 reads: "4-[2-chloro-6-fluoro-4-((1methyl-1H-indazol-5-yl)" should read -- 4-[2-chloro-6-fluoro-4-((1methyl-1H-indazol-5-yl] --.

Column 133, Line 50 reads: "4-[3-fluoro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[3-fluoro-4-((1methyl-1H-indazol-5-yl)amino] --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Millen, White, Zelano & Branigan, P.C.
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201

This collection of information is required by 37 CFR 1.222, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 8,076,488

Page 2 of 4

APPLICATION NO. 10/788,426

ISSUE DATE: December 13, 2011

INVENTOR(S): Jacques DUMAS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 134, Line 18 reads: "N-methyl-4-[3-((1methyl-1H-indazol-5-yl)amino]" should read -- N-methyl-4-[3-((1-methyl-1H-indazol-5-yl)amino) --.

Column 134, Line 24 reads: "4-[2-chloro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[2-chloro-4-((1-methyl-1H-indazol-5-yl)amino) --.

Column 134, Line 45 reads: "4-[3-chloro-4-((1methyl-1H-indazol-5-yl)amino]" should read --4-[3-chloro-4-((1-methyl-1H-indazol-5-yl)amino) --.

Column 134, Line 48 reads: "N-methyl-4-[3-((1methyl-1H-indazol-5-yl)amino]" should read -- N-methyl-4-[3-((1-methyl-1H-indazol-5-yl)amino) --.

Column 134, Line 50 reads: "N-methyl-4-[3-((1methyl-1H-indazol-6-yl)amino]" should read -- N-methyl-4-[3-((1-methyl-1H-indazol-6-yl)amino) --.

Column 134, Line 57 reads: "4-[4-chloro-3-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[4-chloro-3-((1-methyl-1H-indazol-5-yl)amino) --.

Column 134, Line 66 reads: "4-[3-chloro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[3-chloro-4-((1-methyl-1H-indazol-5-yl)amino) --.

Column 135, Line 1 reads: "4-[2-chloro-4-((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[2-chloro-4-((1-methyl-1H-indazol-5-yl)amino) --.

Column 135, Line 11 reads: "N-methyl-4-[4-((1oxo-2,3-dihydro-1H-inden-5-yl)" should read -- N-methyl-4-[4-((1-oxo-2,3-dihydro-1H-inden-5-yl) --.

Column 135, Line 21 reads: "N-methyl-4-[4-((1oxo-2,3-dihydro-1H-inden-5-yl)" should read -- N-methyl-4-[4-((1-oxo-2,3-dihydro-1H-inden-5-yl) --.

Column 135, Line 29 reads: "N-methyl-4-[4-((1methyl-1H-indazol-6-yl)amino]" should read -- N-methyl-4-[4-((1-methyl-1H-indazol-6-yl)amino) --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
 Millen, White, Zelano & Branigan, P.C.
 2200 Clarendon Blvd., Suite 1400
 Arlington, VA 22201

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form, and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 8,076,488

Page 3 of 4

APPLICATION NO. : 10/788,426

ISSUE DATE : December 13, 2011

INVENTOR(S) : Jacques DUMAS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 135, Line 33 reads: "N-methyl-4-[4-((1methyl-1H-indazol-5-yl)amino]" should read .. N-methyl-4-[4-((1-methyl-1H-indazol-5-yl)amino] ..

Column 135, Line 41 reads: "4-[2,4-dichloro-4-((1methyl-1H-indazol-5-yl)amino]" should read .. 4-[2,4-dichloro-5-((1-methyl-1H-indazol-5-yl)amino] ..

Column 135, Line 56 reads: "4-[3-chloro-4-((1oxo-2,3-dihydro-1H-inden-5-yl)" should read .. 4-[3-chloro-4-((1-oxo-2,3-dihydro-1H-inden-5-yl) ..

Column 135, Line 59 reads: "4-[2-chloro-4-((1oxo-2,3-dihydro-1H-inden-5-yl)" should read .. 4-[2-chloro-4-((1-oxo-2,3-dihydro-1H-inden-5-yl) ..

Column 138, Line 37 reads: "4-[4-((1methyl-1H-indazol-5-yl)amino]" should read .. 4-[4-((1-methyl-1H-indazol-5-yl)amino] ..

Column 138, Line 40 reads: "4-[4-((1methyl-1H-indazol-5-yl)amino]" should read .. 4-[4-((1-methyl-1H-indazol-5-yl)amino] ..

Column 139, Line 21 reads: "N-[2-(dimethylamino)-2-oxoethyl]-4-[4-((1methyl-)" should read .. N-[2-(dimethylamino)-2-oxoethyl]-4-[4-((1-methyl- ..

Column 139, Line 27 reads: "N-methyl-4-[4-((1methyl-1H-indazol-5-yl)amino]" should read .. N-methyl-4-[4-((1-methyl-1H-indazol-5-yl)amino] ..

Column 139, Line 32 reads: "Methyl 4-[3-((1methyl-1H-indazol-5-yl)amino]" should read .. Methyl 4-[3-((1-methyl-1H-indazol-5-yl)amino] ..

Column 139, Line 44 reads: "Methyl 4-[4-((1methyl-1H-indazol-5-yl)amino]" should read .. Methyl 4-[4-((1-methyl-1H-indazol-5-yl)amino] ..

Column 139, Line 55 reads: "N-[3-(1H-imidazol-1-yl)propyl]-4-[4-((1methyl-1H-in-]" should read .. N-[3-(1H-imidazol-1-yl)propyl]-4-[4-((1-methyl-1H-in- ..

MAILING ADDRESS OF SENDER (Please do not use customer number below):
 Millen, White, Zelano & Branigan, P.C.
 2200 Clarendon Blvd., Suite 1400
 Arlington, VA 22201

This collection of information is required by 37 CFR 1.222, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 8,076,488

Page 4 of 4

APPLICATION NO. : 10/788,426

ISSUE DATE : December 13, 2011

INVENTOR(S) : Jacques DUMAS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 139, Line 58 reads: "4-[4-(((1methyl-1H-indazol-5-yl)amino]" should read -- 4-[4-(((1methyl-1H-indazol-5-yl)amino] --.

Column 139, Line 61 reads: "N-cyclopropyl-4-[4-(((1methyl-1H-indazol-5-yl)amino]" should read -- N-cyclopropyl-4-[4-(((1methyl-1H-indazol-5-yl)amino] --.

Column 139, Line 63 reads: "N-(cyclopropylmethyl)-4-[4-(((1methyl-1H-indazol-5-yl)amino]" should read -- N-(cyclopropylmethyl)-4-[4-(((1methyl-1H-indazol-5-yl)amino] --.

Column 139, Line 66 reads: "N-cyclobutyl-4-[4-(((1methyl-1H-indazol-5-yl)amino]" should read -- N-cyclobutyl-4-[4-(((1methyl-1H-indazol-5-yl)amino] --.

Column 140, Line 1 reads: "Methyl-N-((4-[4-(((1methyl-1H-indazol-5-yl)amino]" should read -- Methyl-N-((4-[4-(((1methyl-1H-indazol-5-yl)amino] --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Millen, White, Zelano & Branigan, P.C.
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.